• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·688639.SS
Share

Anhui Huaheng Biotechnology Co., Ltd. Stocks

CN¥ 25.02Last Updated 26.05.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

CN¥ 937.96M

CN¥ 25.02
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Slightly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Anhui Huaheng Biotechnology Co., Ltd. engages in the development, production, and sale of amino acids and other organic acids in China and internationally. The company offers L-alanine, DL-alanine, beta-alanine, and D-alanine products; and L-aspartic, DL-aspartic, and D-aspartic acids, as well as L-aspartate salt. It also provides various other amino acids; and arbutin products. Its products are used in medicines and health care products, food and food additives, daily chemicals, and other fields. Anhui Huaheng Biotechnology Co., Ltd. was formerly known as Anhui Huaheng Biological Engineering Co., Ltd. and changed its name to Anhui Huaheng Biotechnology Co., Ltd. in November, 2013. The company was founded in 2005 and is based in Hefei, China.

Company Valuation

Slightly overvalued
3/7

From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. Specifically, the stock is fairly valued on P/E, neutral on E

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

28.05.2026 07:00

The founder of Yardeni is not expecting a market bubble. He named the main driver of the year

28.05.2026 03:46

Boeing has been authorized to increase production of the 737 Max. It is its best-selling airliner

28.05.2026 01:26

All three major U.S. indexes hit records - the first time that has happened this year

27.05.2026 23:51

JPMorgan in search of a big deal: Dimon admits to a takeover worth up to $20 billion

27.05.2026 23:18

Has the energy shock reached Europe? Britons' energy costs set to soar to a two-year peak

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026